Lisa A Carey

List of Publications by Year in Descending Order

234 papers	22,761 citations	70 h-index	148 g-index
258 ext. papers	27,135 ext. citations	7.6 avg, IF	6.61 L-index

#	Paper	IF	Citations
234	The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer.. *Clinical Cancer Research*, **2022**,	12.9	1
233	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2101506	2.2	7
232	Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. *Pharmacogenetics and Genomics*, **2021**, 31, 48-52	1.9	
231	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. *JCO Oncology Practice*, **2021**, OP2100482	2.3	1
230	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. *Future Oncology*, **2021**, 17, 4665-4676	3.6	0
229	Benchmarks for Academic Oncology Faculty. *JCO Oncology Practice*, **2021**, 17, e440-e444	2.3	
228	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *New England Journal of Medicine*, **2021**, 384, 1529-1541	59.2	108
227	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). *Annals of Surgical Oncology*, **2021**, 28, 5960-5971	3.1	5
226	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). *JNCI Cancer Spectrum*, **2021**, 5, pkab025	4.6	0
225	ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). *Annals of Surgical Oncology*, **2021**, 28, 436-437	3.1	
224	Finding the positive in triple-negative breast cancer.. *Nature Cancer*, **2021**, 2, 476-478	15.4	1
223	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. *Journal of Clinical Oncology*, **2021**, 39, 1485-1505	2.2	102
222	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. *Npj Breast Cancer*, **2021**, 7, 51	7.8	4
221	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2021**, 27, 4883-4897	12.9	5
220	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. *Journal of Clinical Oncology*, **2021**, 39, 3938-3958	2.2	11
219	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. *JNCI Cancer Spectrum*, **2021**, 5, pkaa072	4.6	3
218	Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. *Cancer*, **2021**, 127, 957-967	6.4	1

217	Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer. *Cancer*, **2021**, 127, 922-930	6.4	5
216	The Global Landscape of Treatment Standards for Breast Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 1143-1155	9.7	8
215	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. *Clinical Cancer Research*, **2021**, 27, 3116-3125	12.9	3
214	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. *EBioMedicine*, **2021**, 69, 103451	8.8	3
213	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. *Journal of Clinical Oncology*, **2021**, 39, 2247-2256	2.2	3
212	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. *Lancet Oncology, The*, **2021**, 22, 1139-1150	21.7	24
211	A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. *Future Oncology*, **2021**, 17, 3911-3924	3.6	2
210	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Annals of Oncology*, **2021**, 32, 1216-1235	10.3	44
209	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. *Journal of Clinical Oncology*, **2020**, 38, 2610-2619	2.2	134
208	Integrating biology and access to care in addressing breast cancer disparities: 25 years of research experience in the Carolina Breast Cancer Study. *Current Breast Cancer Reports*, **2020**, 12, 149-160	0.8	0
207	Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. *Clinical Cancer Research*, **2020**, 26, 4911-4920	12.9	4
206	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. *Clinical Cancer Research*, **2020**, 26, 2783-2788	12.9	12
205	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2020**, 84, 101965	14.4	39
204	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. *Journal of Clinical Oncology*, **2020**, 38, 1346-1366	2.2	249
203	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 545-563	5	82
202	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. *Journal of Clinical Investigation*, **2020**, 130, 4871-4887	15.9	15
201	Weight trajectories in women receiving systemic adjuvant therapy for breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 709-720	4.4	10
200	Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women. *Journal of the National Cancer Institute*, **2020**, 112, 728-736	9.7	5

199	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *New England Journal of Medicine*, **2020**, 382, 597-609	59.2	396
198	Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker,. *JNCI Cancer Spectrum*, **2020**, 4, pkaa082	4.6	3
197	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. *Journal of Clinical Oncology*, **2020**, 38, 4184-4193	2.2	28
196	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *Lancet Oncology, The*, **2020**, 21, 1455-1464	21.7	20
195	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. *Journal of Clinical Oncology*, **2020**, 38, 4274-4282	2.2	92
194	A chemotherapy privileging process for advanced practice providers at an academic medical center. *Journal of Oncology Pharmacy Practice*, **2020**, 26, 116-123	1.7	1
193	Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. *Breast Cancer Research and Treatment*, **2020**, 179, 185-195	4.4	4
192	Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. *Cancer*, **2020**, 126, 3084-3093	6.4	8
191	Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. *PLoS ONE*, **2019**, 14, e0211488	3.7	6
190	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. *Journal of Clinical Oncology*, **2019**, 37, 2189-2192	2.2	7
189	Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. *Cancer*, **2019**, 125, 2945-2954	6.4	34
188	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). *Breast Cancer Research and Treatment*, **2019**, 176, 303-310	4.4	8
187	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. *Breast Cancer Research and Treatment*, **2019**, 176, 321-328	4.4	10
186	Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). *Oncologist*, **2019**, 24, e284-e291	5.7	2
185	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. *Journal of Clinical Oncology*, **2019**, 37, 714-722	2.2	26
184	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. *Oncologist*, **2019**, 24, 762-771	5.7	26
183	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. *Journal of Clinical Oncology*, **2019**, 37, 1868-1875	2.2	120
182	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet, The*, **2019**, 393, 1440-1452	40	137

181	Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study. *Cancer*, **2019**, 125, 3985-3992	6.4	11
180	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. *JNCI Cancer Spectrum*, **2019**, 3, pkz049	4.6	4
179	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. *Journal of Clinical Oncology*, **2019**, 37, 2338-2348	2.2	25
178	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. *JNCI Cancer Spectrum*, **2019**, 3, pkz050	4.6	6
177	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. *Journal of Clinical Oncology*, **2019**, 37, 571-571	2.2	4
176	Research priorities in prediction of response in early breast cancer. *Breast*, **2019**, 48 Suppl 1, S31-S33	3.6	0
175	HITTING A MOVING TARGET: 2019 STANDARDS OF CARE AND TREATMENT OPTIMIZATION FOR HER2+ ABC. *Breast*, **2019**, 48, S29-S30	3.6	
174	Endocrine Therapy Nonadherence and Discontinuation in Black and White Women. *Journal of the National Cancer Institute*, **2019**, 111, 498-508	9.7	29
173	PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. *Cancer Prevention Research*, **2018** , 11, 327-336	3.2	7
172	Influence of provider factors and race on uptake of breast cancer gene expression profiling. *Cancer*, **2018**, 124, 1743-1751	6.4	4
171	Asparagine bioavailability governs metastasis in a model of breast cancer. *Nature*, **2018**, 554, 378-381	50.4	234
170	A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. *Clinical Breast Cancer*, **2018**, 18, 289-297	3	15
169	Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?. *Breast Cancer Research and Treatment*, **2018**, 167, 235-248	4.4	6
168	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 5292-5304	12.9	41
167	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2018**, 171, 111-120	4.4	21
166	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. *Journal of Clinical Investigation*, **2018**, 128, 1371-1383	15.9	83
165	Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. *Journal of the National Cancer Institute*, **2018**, 110,	9.7	62
164	Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. *Clinical Breast Cancer*, **2018**, 18, 29-37	3	24

163	Financial Impact of Breast Cancer in Black Versus White Women. *Journal of Clinical Oncology*, **2018**, 36, 1695-1701	2.2	56
162	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 78-86	7.1	20
161	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. *Breast Cancer Research and Treatment*, **2018**, 171, 637-648	4.4	22
160	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). *Journal of the American College of Surgeons*, **2017**, 224, 688-694	4.4	5
159	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. *Cancer Discovery*, **2017**, 7, 302-321	24.4	80
158	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). *Journal of Clinical Oncology*, **2017**, 35, 1061-1069	2.2	164
157	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. *JAMA Oncology*, **2017**, 3, 1043-1050	13.4	67
156	Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review. *Breast Cancer Research and Treatment*, **2017**, 162, 375-388	4.4	12
155	Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer. *JNCI Cancer Spectrum*, **2017**, 1, pkx004	4.6	2
154	Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *Breast Cancer Research and Treatment*, **2017**, 165, 181-191	4.4	37
153	Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. *Journal of Clinical Oncology*, **2017**, 35, 3298-3305	2.2	31
152	Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). *Breast Cancer Research and Treatment*, **2017**, 166, 793-808	4.4	6
151	De-escalating and escalating systemic therapy in triple negative breast cancer. *Breast*, **2017**, 34 Suppl 1, S112-S115	3.6	7
150	Treating Triple Negative ABC. *Breast*, **2017**, 36, S30-S31	3.6	
149	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. *Journal of Clinical Investigation*, **2017**, 127, 3472-3483	15.9	84
148	Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. *Breast Cancer Research*, **2016**, 18, 79	8.3	64
147	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). *Breast Cancer Research and Treatment*, **2016**, 159, 109-18	4.4	26
146	Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. *Journal of the American College of Surgeons*, **2016**, 223, 717-728.e4	4.4	16

145	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). *Breast Cancer Research and Treatment*, **2016**, 160, 297-304	4.4	42
144	Breast Cancer Screening in Low- and Middle-Income Countries: A Perspective From Malawi. *Journal of Global Oncology*, **2016**, 2, 4-8	2.6	24
143	Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 130-8	2.2	39
142	A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. *Oncologist*, **2016**, 21, 16-20	5.7	22
141	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. *JAMA Oncology*, **2016**, 2, 29-36	13.4	48
140	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. *Journal of Clinical Oncology*, **2016**, 34, 542-9	2.2	242
139	Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. *PLoS Medicine*, **2016**, 13, e1002174	11.6	62
138	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). *Npj Breast Cancer*, **2016**, 2,	7.8	58
137	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. *Oncologist*, **2016**, 21, 795-803	5.7	28
136	Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 2003-9	2.2	39
135	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. *JAMA Oncology*, **2016**, 2, 1557-1564	13.4	168
134	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). *Journal of Clinical Oncology*, **2016**, 34, 2602-9	2.2	77
133	The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. *Journal of Biopharmaceutical Statistics*, **2015**, 25, 66-88	1.3	7
132	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). *Journal of Clinical Oncology*, **2015**, 33, 2361-9	2.2	157
131	Old drugs, new tricks for triple-negative breast cancer. *Lancet Oncology, The*, **2015**, 16, 357-9	21.7	6
130	Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. *Breast Cancer Research and Treatment*, **2015**, 150, 667-74	4.4	32
129	Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*, **2015**, 20, 474-82	5.7	102
128	Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). *Breast Cancer Research and Treatment*, **2015**, 151, 589-96	4.4	46

127	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. *Journal of Clinical Oncology*, **2015**, 33, 1902-9	2.2	281
126	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. *Cell Reports*, **2015**, 11, 390-404	10.6	210
125	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. *Breast Cancer Research and Treatment*, **2015**, 152, 347-56	4.4	37
124	Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. *Breast Cancer Research and Treatment*, **2015**, 153, 191-200	4.4	15
123	Neoadjuvant clinical trial designs: Challenges of the genomic era. *Breast*, **2015**, 24 Suppl 2, S88-90	3.6	2
122	Circulating tumor cell analysis in metastatic triple-negative breast cancers. *Clinical Cancer Research*, **2015**, 21, 1098-105	12.9	33
121	TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. *Journal of Nuclear Medicine*, **2015**, 56, 31-7	8.9	48
120	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *Journal of Clinical Oncology*, **2015**, 33, 13-21	2.2	590
119	In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. *British Journal of Clinical Pharmacology*, **2015**, 80, 1122-30	3.8	30
118	CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. *Clinical Cancer Research*, **2015**, 21, 4027-9	12.9	3
117	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *New England Journal of Medicine*, **2015**, 372, 134-41	59.2	455
116	The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. *Annals of Surgical Oncology*, **2015**, 22, 874-82	3.1	74
115	Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. *Cancer Research*, **2014**, 74, 2160-70	10.1	115
114	B-crystallin: a novel regulator of breast cancer metastasis to the brain. *Clinical Cancer Research*, **2014**, 20, 56-67	12.9	70
113	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2014**, 32, 3307-29	2.2	185
112	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. *Breast Cancer Research and Treatment*, **2014**, 146, 557-66	4.4	48
111	Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. *Breast Cancer Research and Treatment*, **2014**, 145, 245-54	4.4	34
110	A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. *Breast Cancer Research and Treatment*, **2014**, 148, 99-106	4.4	10

109	Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. *Science Signaling*, **2014**, 7, ra29	8.8	93
108	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	132
107	Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. *Journal of the National Cancer Institute*, **2014**, 106, dju057	9.7	157
106	Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. *Oncologist*, **2014**, 19, 1076-83	5.7	85
105	Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. *Clinical Cancer Research*, **2014**, 20, 3818-29	12.9	168
104	Defining success in neoadjuvant breast cancer trials. *Lancet, The*, **2014**, 384, 115-6	40	12
103	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).. *Journal of Clinical Oncology*, **2014**, 32, 506-506	2.2	11
102	Understanding how breast cancer patients use risk information from genomic tests. *Journal of Behavioral Medicine*, **2013**, 36, 567-73	3.6	13
101	The management of early-stage and metastatic triple-negative breast cancer: a review. *Hematology/Oncology Clinics of North America*, **2013**, 27, 737-49, viii	3.1	64
100	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. *Clinical Cancer Research*, **2013**, 19, 5505-12	12.9	443
99	Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. *Experimental and Molecular Pathology*, **2013**, 95, 276-87	4.4	45
98	Emerging therapies for triple-negative breast cancer. *Breast Cancer Management*, **2013**, 2, 47-55	0.7	0
97	Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. *Oncologist*, **2013**, 18, 986-93	5.7	134
96	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. *Oncologist*, **2013**, 18, 123-33	5.7	376
95	Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. *PLoS ONE*, **2013**, 8, e61359	3.7	67
94	Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.. *Journal of Clinical Oncology*, **2013**, 31, 500-500	2.2	43
93	Engaging in health behaviors to lower risk for breast cancer recurrence. *PLoS ONE*, **2013**, 8, e53607	3.7	24
92	Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. *Annals of Surgical Oncology*, **2012**, 19, 1508-16	3.1	329

91	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. *Breast Cancer Research and Treatment*, **2012**, 136, 35-43	4.4	73
90	Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. *Journal of Clinical Oncology*, **2012**, 30, 3242-9	2.2	318
89	Defining the expressed breast cancer kinome. *Cell Research*, **2012**, 22, 620-3	24.7	21
88	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. *Breast Cancer Research and Treatment*, **2012**, 134, 401-10	4.4	71
87	The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. *Cancer Chemotherapy and Pharmacology*, **2012**, 69, 1189-96	3.5	14
86	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. *Breast Cancer Research and Treatment*, **2012**, 132, 523-35	4.4	165
85	Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). *Breast Cancer Research and Treatment*, **2012**, 132, 871-9	4.4	20
84	Improving communication of breast cancer recurrence risk. *Breast Cancer Research and Treatment*, **2012**, 133, 553-61	4.4	55
83	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *Breast Cancer Research and Treatment*, **2012**, 132, 1049-62	4.4	252
82	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. *Breast Cancer Research and Treatment*, **2012**, 133, 1057-65	4.4	166
81	ACR appropriateness criteria( ) ductal carcinoma in situ. *Breast Journal*, **2012**, 18, 8-15	1.2	18
80	ACR Appropriateness Criteria local-regional recurrence (LR) and salvage surgery: breast cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2012**, 35, 178-82	2.7	11
79	Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. *Oncologist*, **2012**, 17, 1496-503	5.7	8
78	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 2615-23	2.2	359
77	PARP and cancer--if it broke, don fix it. *New England Journal of Medicine*, **2011**, 364, 277-9	59.2	43
76	ACR Appropriateness Criteria conservative surgery and radiation--stage I and II breast carcinoma: expert panel on radiation oncology: breast. *Breast Journal*, **2011**, 17, 448-55	1.2	24
75	ACR appropriateness criteria locally advanced breast cancer. *Breast Journal*, **2011**, 17, 579-85	1.2	13
74	Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. *Annals of Surgical Oncology*, **2011**, 18, 2851-7	3.1	73

73	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. *BMC Medical Genomics*, **2011**, 4, 3	3.7	104
72	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. *Cancer*, **2011**, 117, 1602-11	6.4	110
71	Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. *Journal of Clinical Oncology*, **2011**, 29, 3232-9	2.2	157
70	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nature Genetics*, **2011**, 43, 1210-4	36.3	253
69	Directed therapy of subtypes of triple-negative breast cancer. *Oncologist*, **2011**, 16 Suppl 1, 71-8	5.7	126
68	Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?. *Journal of Clinical Oncology*, **2011**, 29, e18-20	2.2	152
67	Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. *American Surgeon*, **2011**, 77, 850-5	0.8	11
66	Novel targets for triple-negative breast cancer. *Clinical Advances in Hematology and Oncology*, **2011**, 9, 678-80	0.6	2
65	Clinical trials in triple negative breast cancer. *Breast Disease*, **2010**, 32, 123-36	1.6	24
64	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. *Molecular Cancer Research*, **2010**, 8, 701-16	6.6	44
63	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. *Clinical Cancer Research*, **2010**, 16, 4702-10	12.9	120
62	Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. *Clinical Cancer Research*, **2010**, 16, 6100-10	12.9	286
61	Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. *Journal of Clinical Oncology*, **2010**, 28, 361-3	2.2	33
60	Directed therapy of subtypes of triple-negative breast cancer. *Oncologist*, **2010**, 15 Suppl 5, 49-56	5.7	41
59	Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. *Clinical Breast Cancer*, **2010**, 10, 188-95	3	32
58	Triple-negative breast cancer: disease entity or title of convenience?. *Nature Reviews Clinical Oncology*, **2010**, 7, 683-92	19.4	588
57	Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. *Clinical Breast Cancer*, **2010**, 10, 465-70	3	22
56	Women© experiences with genomic testing for breast cancer recurrence risk. *Cancer*, **2010**, 116, 1992-2000	6.4	42

55	Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. *JAMA - Journal of the American Medical Association*, **2009**, 302, 774-80	27.4	206
54	Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. *Seminars in Radiation Oncology*, **2009**, 19, 204-10	5.5	82
53	A compact VEGF signature associated with distant metastases and poor outcomes. *BMC Medicine*, **2009**, 7, 9	11.4	132
52	Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. *Journal of the American College of Surgeons*, **2009**, 208, 906-14; discussion 915-6	4.4	64
51	When genomic and standard test results diverge: implications for breast cancer patientsO preference for chemotherapy. *Breast Cancer Research and Treatment*, **2009**, 117, 25-9	4.4	19
50	Reporting of race and ethnicity in breast cancer research: room for improvement. *Breast Cancer Research and Treatment*, **2009**, 118, 511-7	4.4	14
49	CYP2D6 and tamoxifen: DNA matters in breast cancer. *Nature Reviews Cancer*, **2009**, 9, 576-86	31.3	242
48	A desensitization protocol for the mAb cetuximab. *Journal of Allergy and Clinical Immunology*, **2009**, 123, 260-2	11.5	33
47	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. *Clinical Breast Cancer*, **2009**, 9 Suppl 2, S73-81	3	424
46	Molecular subtypes in breast cancer evaluation and management: divide and conquer. *Cancer Investigation*, **2008**, 26, 1-10	2.1	150
45	What is triple-negative breast cancer?. *European Journal of Cancer*, **2008**, 44, 2799-805	7.5	230
44	Triple-negative breast cancer: risk factors to potential targets. *Clinical Cancer Research*, **2008**, 14, 8010-8	12.9	336
43	Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?. *Expert Review of Anticancer Therapy*, **2008**, 8, 191-4	3.5	1
42	Research issues affecting preoperative systemic therapy for operable breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 806-13	2.2	54
41	Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2008**, 6, 505-13; quiz 514	7.3	55
40	Epidemiology of basal-like breast cancer. *Breast Cancer Research and Treatment*, **2008**, 109, 123-39	4.4	651
39	A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. *Cancer Chemotherapy and Pharmacology*, **2008**, 63, 99-107	3.5	18
38	Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. *Molecular Carcinogenesis*, **2008**, 47, 88-99	5	21

37	Understanding and treating triple-negative breast cancer. *Oncology*, **2008**, 22, 1233-9; discussion 1239-40, 1243	1.8	167
36	Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. *Oncology Reports*, **2008**, 19, 1311-21	3.5	31
35	Basal-like breast cancers express a hypermethylation defect. *FASEB Journal*, **2008**, 22, 898.23	0.9	
34	EGFR associated expression profiles vary with breast tumor subtype. *BMC Genomics*, **2007**, 8, 258	4.5	208
33	Molecular profiling in breast cancer. *Reviews in Endocrine and Metabolic Disorders*, **2007**, 8, 185-98	10.5	34
32	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. *Translational Medicine Series*, **2007**, 103-120		
31	Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. *Radiology*, **2007**, 245, 824-30	20.5	34
30	Gene-expression analysis and the basal-like breast cancer subtype. *Future Oncology*, **2007**, 3, 55-63	3.6	29
29	Women interest in gene expression analysis for breast cancer recurrence risk. *Journal of Clinical Oncology*, **2007**, 25, 4628-34	2.2	38
28	Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 249-55	4	69
27	Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. *Clinical Cancer Research*, **2007**, 13, 3637-41	12.9	69
26	Gene expression profiling in breast cancer. *Current Opinion in Oncology*, **2007**, 19, 547-51	4.2	40
25	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clinical Cancer Research*, **2007**, 13, 2329-34	12.9	1534
24	The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics* , **2006**, 7, 96	4.5	1016
23	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA - Journal of the American Medical Association*, **2006**, 295, 2492-502	27.4	2683
22	Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. *Carcinogenesis*, **2006**, 27, 2519-27	4.6	14
21	Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. *Journal of Clinical Oncology*, **2006**, 24, 1656-64	2.2	275
20	Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. *Clinical Breast Cancer*, **2006**, 7, 237-43	3	32

19	Axillary lymph node count is lower after neoadjuvant chemotherapy. *American Journal of Surgery*, **2006**, 191, 827-9	2.7	57
18	Clonal evolution of lymphoblastoid cell lines. *Laboratory Investigation*, **2006**, 86, 1193-200	5.9	28
17	Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic. *Annals of Surgical Oncology*, **2006**, 13, 685-91	3.1	56
16	Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. *Cancer Research*, **2005**, 65, 9155-8	10.1	264
15	Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. *American Journal of Surgery*, **2005**, 190, 371-5	2.7	30
14	Current treatment paradigms for the management of patients with brain metastases. *Neurosurgery* , **2005**, 57, S66-77; discusssion S1-4	3.2	58
13	American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. *Journal of the National Cancer Institute*, **2005**, 97, 1137-42	9.7	153
12	Central nervous system metastases in women after multimodality therapy for high risk breast cancer. *Breast Cancer Research and Treatment*, **2004**, 88, 273-80	4.4	47
11	Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. *Cancer Immunology, Immunotherapy*, **2004**, 53, 777-85	7.4	30
10	High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. *American Journal of Surgery*, **2004**, 188, 386-9	2.7	17
9	Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma. *Annals of Surgery*, **2002**, 236, 295-303	7.8	107
8	Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. *Annals of Surgery*, **2002**, 236, 295-302; discussion 302-3	7.8	42
7	Brain metastases. *Current Treatment Options in Oncology*, **2001**, 2, 537-47	5.4	23
6	Clinical significance of micrometastatic disease in the era of sentinel node. *Breast Disease*, **2001**, 12, 57-67	1.6	1
5	Telomerase activity and prognosis in primary breast cancers. *Journal of Clinical Oncology*, **1999**, 17, 3075-81	22.1	46
4	Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Longcope Firm of the Osler Medical Housestaff. *American Journal of Medicine*, **1996**, 100, 186-92	2.4	26
3	Treatment of melanoma metastases in the brain. *Journal of Surgical Oncology*, **1996**, 12, 429-35		33
2	Quantifying the effect of ischemia on epiphyseal growth in an extremity replant model. *Journal of Hand Surgery*, **1990**, 15, 625-30	2.6	16

1	Oxygen radical scavengers improve vascular patency and bone-muscle cell survival in an ischemic extremity replant model. *Plastic and Reconstructive Surgery*, **1989**, 84, 117-23	2.7	21